Business Wire

Life Biosciences Acquires Lua, Pioneering AI-Driven Healthcare Platform

Del

Life Biosciences today announced it is acquiring Lua, the communication and technology platform. This bold step is intended to facilitate the creation of a proprietary artificial intelligence (AI) platform, designed to accelerate Life Biosciences’ research for novel therapies, technologies and drugs to combat age-related decline (ARD). Life Biosciences is the first and largest biotech company focused on addressing health decline due to aging as a systemic breakdown of the body, rather than a series of isolated events and conditions.

Lua is a web- and mobile-access technology platform focused on improving patient outcomes by facilitating communication between providers and patients. Within Life Biosciences, Lua’s technology will be developed into a platform that is expected to allow faster, comprehensive analysis of study data and the integration of information from scientific studies being conducted by each of the ‘Daughter companies’ within Life Biosciences’ Dream Team business model.

This capability will support all of Life Biosciences’ research to help humans and animals live longer, healthier lives, by ensuring better and faster development of drugs and other treatments. Lua’s direct-to-patient communication model is already at work with demanding healthcare providers, such as Aces ABA, Hospice Partners of America, and The Ensign Group.

“Our Daughter companies are led by the world’s most eminent researchers on age-related decline and longevity,” said Tristan Edwards, co-founder and chief executive officer of Life Biosciences. “Their work will extend into human trials, and for that reason we are thrilled to acquire the powerful Lua platform, which will be available to each of our companies as a proven system for communicating in a HIPAA-compliant environment enabling rich interactivity with a user-friendly interface.”

– Lua: Connective Platform –

“We are excited to be joining the Life Biosciences family,” said Michael DeFranco, Lua co-founder. “Lua's focus, to improve outcomes by streamlining access between healthcare providers and patients, fits perfectly with Life Biosciences’ mission to increase healthy lifespans for all. By creating real-time feedback loops, we expect to bring data-led insights to researchers in clinical trials that were not feasible earlier. We firmly believe our direct-to-consumer technology has the potential to change pet and ultimately human life as we know it.”

Lua, founded in 2010, will continue to be operated as a separate company by its co-founders, DeFranco and Jason Krigsfeld. Beyond its primary role in healthcare, the company’s platform is also available to enterprise customers in financial services, hospitality and event planning. Its intuitive and real-time architecture allows for team-based and customer-based communication.

Nick Ventresca, chief technology officer of Life Biosciences, noted, “All drug development is based upon the insightful and privacy-protective use of data and information. We will utilize the Lua platform for not only drug development, but also in the future to securely bring information to patients and caregivers around the world.”

– Life Biosciences Overview –

Life Biosciences was co-founded in 2017 by David Sinclair, PhD, a professor in the Department of Genetics at Harvard Medical School, and Tristan Edwards, who developed its innovative structure as Chapter Two in his life, after a highly successful career as a global institutional investor, working across all asset classes.

The company’s novel Daughter company business model creates the robust research ecosystem required to forge industry leadership through two investment strategies. The first is to establish new companies, thereby extending the research of visionary scientists around the world. Secondly, Life Biosciences invests in other groundbreaking firms, providing them with the resources to maximize their potential.

In addition to Lua, there are six Daughter companies working independently and together within the Life Biosciences research environment. The company provides Daughter companies with the resources required to maximize human potential, including Lua’s AI-driven data and communications platform, experienced management, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility in Cambridge, Mass, augmented by laboratories and offices on four continents.

Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest biotech company addressing the eight pathways of age-related decline (ARD) in totality. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with resources to maximize human potential, including Lua’s AI-driven data and communications platform, drug development experience, and a 25,000 square foot, state-of-the-art vivarium, robotics and drug screening facility. Life Biosciences seeks to increase healthspans for everyone, including companion animals, by addressing the systemic breakdown of the body, rather than as a series of isolated symptoms and conditions.

For more information on Life Biosciences, please visit www.lifebiosciences.com.

Contact information

Life Biosciences
Erin Foster
erinf@lifebiosciences.com
or
media@lifebiosciences.com
or
susanm@lifebiosciences.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Moon-Walking Mini-Breaks, 3D-Printed Room Service and Hyper-Personalised Spaces: Welcome to the Hotel of 211919.6.2019 10:05:00 CESTPressemelding

Intergalactic getaways, fast-food nutrient pills, 2-3 hour working days and adaptable, personalised rooms that can transport guests everywhere from jungles to mountain ranges; in celebration of its 100th anniversary, today Hilton (NYSE: HLT) predicts the future trends set to dominate the travel and hospitality industry in the next 100 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005341/en/ Autonomous shooting travel pods will drop guests off at mesmerising destinations, while miniature eco-systems protected from the elements by bubble-like structures will mirror their surroundings (Photo: Business Wire) In a report supported by expert insight from the fields of sustainability, innovation, design, human relations and nutrition, findings reveal how the growing sophistication of technology and climate change will impact the hotel industry in the future. Key predictions for the hotel of the future include: Persona

Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA19.6.2019 10:00:00 CESTPressemelding

Invivoscribe is pleased to announce that on June 5th the Ministry of Health, Labor and Welfare (MHLW) approved our LeukoStrat® CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo’s Quizartinib for the treatment of FLT3-ITD positive relapse/ refractory acute myeloid leukemia (AML) patients in Japan. At the same time the Japanese MHLW added approval in use of EDTA collection tubes to the existing approval of heparin collection tubes used with this assay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005222/en/ Invivoscribe Headquarters - San Diego, CA (Photo: Business Wire) The QuANTUM-R study demonstrated that quizartinib resulted in a statistically significant improvement in overall survival (OS) compared to salvage chemotherapy when patients were selected with the LeukoStrat CDx FLT3 Mutation Assay. Mutations in the FLT3 gene are among the most important driver mutations in AML. This milestone furt

BearingPoint Acquires Public Services Consultancy Prederi in the UK19.6.2019 08:50:00 CESTPressemelding

Management and technology consultancy BearingPoint made a strategic move by acquiring Prederi, a leading consultancy focused on public services in the UK. The acquisition supports BearingPoint’s overall growth objectives, strengthens its presence in the UK, and broadens its public service capabilities. With this transaction, two highly profitable companies join forces. Prederi provides expert advice and consultancy and serves a large number of prestigious UK public sector clients. For many years, Prederi has been generating stable revenue streams. The Prederi team now expands BearingPoint’s expertise and capabilities in one of the largest and most competitive public services markets in Europe. “With the acquisition of Prederi we are continuing our growth strategy in selected markets with consultancies that are highly focused and strongly differentiated,” said Kiumars Hamidian, Managing Partner of BearingPoint. “Prederi's portfolio is a perfect complement to our public service strategy

HCL Technologies Selected by Cricket Australia as Digital Technology Partner19.6.2019 07:52:00 CESTPressemelding

HCL Technologies (HCL) and Cricket Australia (CA) have today announced a multi-year partnership, with HCL being chosen as the Digital Technology Partner of CA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005284/en/ HCL Technologies and Cricket Australia exchanging mementos to announce digital partnership. Standing left to right: Brad Hodge, former Australian international cricketer, & current cricket coach; Arthur Fillip, Executive Vice President - Sales Transformation & Marketing; Kevin Roberts, CEO, Cricket Australia; Swapan Johri, Corporate Vice President & Head - Asia/Pacific & Middle East Business; Belinda Clarke, Executive General Manager, Community Cricket & former captain of the Australian Women's Cricket Team (Photo: Business Wire) HCL, a leading global technology company, will help the Australian cricket’s governing body provide an elevated and immersive digital experience to cricket fans, players, partner

Sartorius Starts up Operations at Expanded Site in Puerto Rico19.6.2019 07:30:00 CESTPressemelding

After investing more than 100 million U.S. dollars, Sartorius, a leading international partner of biopharmaceutical research and the industry, started up its expanded manufacturing operations in Yauco, Puerto Rico. The U.S. market is primarily supplied from this site, given that Sartorius has been growing strongly in this marketplace at above-average rates over the past several years. “Operationally and strategically, this expansion is an important investment for us. The considerably higher production capacities created as a result now give us leeway to deliver an even wider product array directly from the region to our American customers and to implement our ambitious growth plans in the Americas,” said Sartorius Executive Board Chairman and CEO Joachim Kreuzburg to approximately 500 employees and guests at the opening ceremony on Tuesday in Yauco. The company substantially extended the plant in Puerto Rico within a construction phase of around three years, more than doubling producti

comforte AG Gives Apache Kafka a Big Data Security Boost19.6.2019 07:14:00 CESTPressemelding

comforte AG, a leading provider of enterprise data security and digital payments solutions, has announced new integration capabilities for Apache Kafka with the latest release of its Enterprise Data Protection Suite. Apache Kafka is a distributed data streaming platform that allows users to collect and examine real-time data streams from a variety of popular applications. These new capabilities enable organizations to integrate data protection methods, like tokenization or format-preserving encryption, into their Kafka environments. Anonymization and pseudonymization can be applied to sensitive data on the fly within Apache Kafka to help organizations protect information and fulfil compliance regulations. The additional capabilities cater to use cases unique to the Apache Kafka environment, especially Kafka Connect and Kafka Streams. The release will be making its debut at Whitehall Media’s Big Data Analytics Conference in London, the industry event showcasing the latest Big Data Analy